Evidence map›Paper›PMID 38201630›Full record

ArticleCancers2024

Development and Validation of an Explainable Radiomics Model to Predict High-Aggressive Prostate Cancer: A Multicenter Radiomics Study Based on Biparametric MRI.

Giulia Nicoletti, Simone Mazzetti, Giovanni Maimone, Valentina Cignini, Renato Cuocolo, Riccardo Faletti, Marco Gatti, Massimo Imbriaco, Nicola Longo, Andrea Ponsiglione and 5 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Giulia NicolettiDepartment of Electronics and Telecommunications, Polytechnic of Turin, Corso Duca degli Abruzzi, 24, 10129 Turin, Italy.ORCID 0000-0003-2013-5933
Simone MazzettiRadiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale, 142-KM 3.95, 10060 Candiolo, Italy.ORCID 0000-0001-6011-4040
Giovanni MaimoneRadiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale, 142-KM 3.95, 10060 Candiolo, Italy.
Valentina CigniniDepartment of Surgical Sciences, University of Turin, Corso Dogliotti, 14, 10126 Turin, Italy.ORCID 0000-0001-5962-8896
Renato CuocoloDepartment of Medicine, Surgery, and Dentistry, University of Salerno, Via Salvador Allende, 43, 84081 Baronissi, Italy.ORCID 0000-0002-1452-1574
Riccardo FalettiDepartment of Surgical Sciences, University of Turin, Corso Dogliotti, 14, 10126 Turin, Italy.
Marco GattiDepartment of Surgical Sciences, University of Turin, Corso Dogliotti, 14, 10126 Turin, Italy.
Massimo ImbriacoDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini, 5, 80131 Naples, Italy.ORCID 0000-0001-5262-5430
Nicola LongoDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Via Pansini, 5, 80131 Naples, Italy.
Andrea PonsiglioneDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini, 5, 80131 Naples, Italy.ORCID 0000-0002-0105-935X
Filippo RussoRadiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale, 142-KM 3.95, 10060 Candiolo, Italy.
Alessandro SerafiniDepartment of Surgical Sciences, University of Turin, Corso Dogliotti, 14, 10126 Turin, Italy.ORCID 0000-0002-4992-4824
Arnaldo StanzioneDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini, 5, 80131 Naples, Italy.ORCID 0000-0002-7905-5789
Daniele ReggeRadiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale, 142-KM 3.95, 10060 Candiolo, Italy.
Valentina GianniniDepartment of Surgical Sciences, University of Turin, Corso Dogliotti, 14, 10126 Turin, Italy.ORCID 0000-0001-5052-8231

Funding

European Union's Horizon 2020 research and innovation program grant agreement no 952159Italian Association for Cancer Research IG2017 - ID.20398 project - P.I. Regge Daniele.
6 · The paper itself

Abstract

In the last years, several studies demonstrated that low-aggressive (Grade Group (GG) ≤ 2) and high-aggressive (GG ≥ 3) prostate cancers (PCas) have different prognoses and mortality. Therefore, the aim of this study was to develop and externally validate a radiomic model to noninvasively classify low-aggressive and high-aggressive PCas based on biparametric magnetic resonance imaging (bpMRI). To this end, 283 patients were retrospectively enrolled from four centers. Features were extracted from apparent diffusion coefficient (ADC) maps and T2-weighted (T2w) sequences. A cross-validation (CV) strategy was adopted to assess the robustness of several classifiers using two out of the four centers. Then, the best classifier was externally validated using the other two centers. An explanation for the final radiomics signature was provided through Shapley additive explanation (SHAP) values and partial dependence plots (PDP). The best combination was a naïve Bayes classifier trained with ten features that reached promising results, i.e., an area under the receiver operating characteristic (ROC) curve (AUC) of 0.75 and 0.73 in the construction and external validation set, respectively. The findings of our work suggest that our radiomics model could help distinguish between low- and high-aggressive PCa. This noninvasive approach, if further validated and integrated into a clinical decision support system able to automatically detect PCa, could help clinicians managing men with suspicion of PCa.

Indexed as

explainable artificial intelligencefeature extractionmagnetic resonance imagingprostate cancerradiomicstumor aggressiveness

Identifiers

PMID38201630
PMCPMC10778513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.